Source review: 6 October 2026. Assess the actual substance and intended use; this editorial guide is not an FDA approval, legal opinion or service-processing guarantee.
Choose the applicable legal basis before selecting a filing
An ingredient authorized abroad is not automatically lawful for the same use in the US. First document identity, composition, specifications, impurities, manufacturing process, technical effect, food categories, proposed levels, cumulative dietary exposure and applicable limits. A change in supplier, process, specification or intended use can change the regulatory assessment.
The available basis may be an existing applicable food-additive regulation, a properly substantiated GRAS conclusion, a valid prior sanction for its covered use, or another applicable statutory route. If a food-additive use is not covered, a petition may be needed to obtain a regulation before use. Do not assume that every new-to-you ingredient requires a new petition or a GRAS notification. Check the exact regulation or other evidence and its conditions, not only an ingredient name in a list.
Under current 21 CFR 170.205, GRAS notification is voluntary. A GRAS conclusion and a voluntary notice are different: the conclusion must satisfy the legal safety/general-recognition criteria whether or not notified. A no-questions letter addresses the notifier’s conclusion for the described use; it is not blanket ingredient approval. FDA can reconsider a GRAS use in light of new information.
FDA GRAS overview: https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras
Current opportunity to notify: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170/subpart-E/section-170.205
August 2026 proposal: not current mandatory-notification law
As checked on 6 October 2026, FDA describes the August proposal as a proposed rule; the current CFR still provides voluntary notification. The proposal was published on 11 August 2026, docket FDA-2025-N-3262, and would generally require notices for human or animal food uses claimed to be GRAS, subject to proposed provisions and exceptions, if finalized. Its proposed obligations, exceptions and transition arrangements are not effective requirements. Recheck for a final rule before relying on a future obligation or effective date.
The published comment deadline is 9 December 2026, with electronic comments accepted through 11:59 p.m. Eastern Time that day. This is a rulemaking-comment deadline, not the food-facility renewal deadline or an ingredient-approval deadline. This article does not submit comments on your behalf.
Proposed rule and dates: https://www.govinfo.gov/content/pkg/FR-2026-08-11/html/2026-16296.htm
GRAS evidence is not automatically a lighter scientific standard
Under 21 CFR 170.30, scientific GRAS requires the same quantity and quality of scientific evidence as food-additive approval, together with general recognition among appropriately qualified experts. Generally available and accepted data, information or methods, ordinarily published, can be corroborated by unpublished evidence. “Everything must be public” and “the petition uses proprietary evidence instead” are both misleading shortcuts.
The separate common-use route concerns food use before 1 January 1958 and a substantial history of consumption by a significant number of consumers, with safety for the intended use. For qualifying foreign pre-1958 use, the rule requires documentation and independent corroboration that are generally available and readily accessible to qualified US experts. Mere foreign authorization or traditional use is not enough. If pre-1958 common use is not established, evaluate the scientific route. Neither route justifies a universal cheaper/faster claim.
GRAS criteria and limits: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170/subpart-B/section-170.30
Petition content, environmental review and disclosure
21 CFR 171.1 requires identity/composition/specifications and manufacturing controls as applicable; intended amount, technical effect and labeling; analytical methods; full safety investigation reports, including relevant unfavorable evidence; tolerances or proposed regulatory changes; and the applicable environmental submission. The environmental requirement is an appropriate categorical-exclusion claim or environmental assessment, not an automatic exemption. Relevant study compliance and English translations also need assessment.
A petition is not uniformly proprietary. Section 171.1(h) provides for disclosure of safety and functionality information at specified filing/deficiency stages, with defined protections and exceptions; manufacturing methods, certain commercial data and formulas can have protected status subject to the rule. Marking information confidential does not guarantee FDA agrees. Referencing another person’s unpublished material or master-file information requires the applicable written permission. Use qualified scientific/environmental review and the actual current filing instructions.
Petition requirements and disclosure: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-171/subpart-A/section-171.1
Timing: filing-based periods are not approval guarantees
Under 21 CFR 170.265, FDA first decides whether to file a submission as a GRAS notice. The response period is 180 days from filing and may be extended by 90 days as needed, with notice of the extension. It does not run automatically from sending an incomplete package, and a response is not necessarily a no-questions letter or a product approval.
The former 12–24-month petition estimate is removed. FDA’s April 2011 Q&A reported a 24-month average from direct-food-additive petition submission to final rule, with variability due to complexity, size and supplements. That historical description is not verified 2026 performance, a fixed deadline or an FDABridge guarantee. Preparation, adequacy, review and legal effectiveness must be assessed separately.
GRAS filing/response rule: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170/subpart-E/section-170.265
Historical April 2011 petition Q&A: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-questions-and-answers-about-food-additive-or-color-additive-petition-process
Examples must match the actual records
FDA has no-questions responses for specified high-purity steviol glycosides, including preparations meeting the described minimum 95% purity and intended uses. Do not imply all steviol glycosides lack a US legal basis. Check the relevant notice, response, identity, process, specifications and use; whole-leaf stevia and crude extracts have a different status for use as sweeteners. For enzymes, fibers, extracts or proteins, a category name alone establishes neither authorization nor lack of it.
FDA sweetener guidance and record links: https://www.fda.gov/food/food-additives-petitions/aspartame-and-other-sweeteners-food
A prior sanction means an explicit FDA or USDA approval before 6 September 1958 for the relevant use, subject to the actual sanction and conditions; it is not any foreign approval or a free-standing permission for a new use. Color additives require the applicable listed use and restrictions; an exemption from batch certification does not mean exemption from authorization. Where required, the batch must be FDA-certified. Do not use a GRAS conclusion to bypass color-additive requirements.
Prior-sanction scope: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-181/subpart-A/section-181.5
Color-additive guidance: https://www.fda.gov/food/food-ingredients-packaging/color-additives-information-consumers
21 CFR 170.39 is a threshold-of-regulation route for qualifying substances used in food-contact articles, not a general exemption for intentionally added direct-food ingredients. Its exposure alternatives, carcinogenicity/impurity criteria, absence of a technical effect in the food, environmental criteria and FDA public-health discretion all matter. Use the existing food-contact guide for that separate task rather than treating low use level alone as legal permission.
Food-contact TOR scope: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-170/subpart-B/section-170.39
Existing food-contact guide: https://fdabridge.com/blog/fda-food-contact-substance-notification-what-foreign-packaging-manufacturers-must-know
Practical ingredient-assessment worksheet — editorial tool
Recommended record, not an FDA form: ingredient identity and supplier; process/version; composition/specifications/impurities; food categories, technical effect and proposed levels; cumulative exposure and sensitive populations; exact legal basis with regulation/notice/sanction reference and limitations; matching evidence and permissions; gaps and owner; qualified scientific/regulatory reviewer and review date; next action and hold point. Keep confidential evidence in controlled records, not a public example.
Illustrative comparison: a specified high-purity steviol preparation matching relevant evidence may follow a different decision path from crude stevia extract. Do not select the route simply because both products are called stevia. A new food category, level or process requires checking coverage and evidence again.
Facility renewal is separate from ingredient legality
Applicable food facilities renew between 1 October and 31 December 2026, even if registered or updated before 1 October. That filing does not authorize an ingredient, approve a product or replace label/safety obligations. FDA’s food-registration/renewal filing fee is zero; independently agreed professional charges are separate. The 9 December GRAS comment date is a different calendar event.
Accurate renewal guide: https://fdabridge.com/blog/fda-food-facility-registration-renewal-2026
For available administrative food-registration or label-review assistance, request a defined scope at https://fdabridge.com/contact . Those services do not by themselves establish GRAS or secure petition approval; a full scientific dossier can require separately qualified expertise. No unverified laboratory, toxicology, petition-filing capability, fee or processing guarantee is asserted.